Impact of new drugs and biologics on colorectal cancer treatment and costs

Pinar Karaca-Mandic, Jeffrey S. McCullough, Mustaqeem A. Siddiqui, Holly Van Houten, Nilay D. Shah

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Objective: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens. Study Design: Using claims data, we identified 2 cohorts of privately insured patients diagnosed with CRC: first, those diagnosed before new treatment introduction (January 1, 2002, to December 31, 2002), and second, those diagnosed after new treatment introduction (June 1, 2004, to May 31, 2005). CRC diagnosis was identified using International Classification of Diseases-9 codes 153.xx, 154.xx, and 159.0. First- and second-line chemotherapy regimens were identified. Treatments and expenditures were then observed for up to 2 years after initial diagnosis. Methods: We estimated multivariate models to measure changes in cost with changes in treatment regimen. Approval dates of new regimens were used as natural experiments. Results: New regimens, such as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), have rapidly replaced the most prevalent preperiod product (ie, fluorouracil/leucovorin). Changes in treatment have caused large increases in total expenditure, primarily through increases in chemotherapy prices. FOLFOX alone has increased total average cost by 14%. New treatments have not substituted for other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes in follow-up duration. Conclusion: New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.

    Original languageEnglish (US)
    JournalAmerican Journal of Managed Care
    Volume17
    Issue number5
    StatePublished - May 1 2011

    Fingerprint

    Biological Products
    Health Care Costs
    Health Expenditures
    Colorectal Neoplasms
    Pharmaceutical Preparations
    oxaliplatin
    Leucovorin
    Therapeutics
    Costs and Cost Analysis
    Fluorouracil
    Drug Therapy
    International Classification of Diseases

    Cite this

    Karaca-Mandic, P., McCullough, J. S., Siddiqui, M. A., Van Houten, H., & Shah, N. D. (2011). Impact of new drugs and biologics on colorectal cancer treatment and costs. American Journal of Managed Care, 17(5).

    Impact of new drugs and biologics on colorectal cancer treatment and costs. / Karaca-Mandic, Pinar; McCullough, Jeffrey S.; Siddiqui, Mustaqeem A.; Van Houten, Holly; Shah, Nilay D.

    In: American Journal of Managed Care, Vol. 17, No. 5, 01.05.2011.

    Research output: Contribution to journalArticle

    Karaca-Mandic, P, McCullough, JS, Siddiqui, MA, Van Houten, H & Shah, ND 2011, 'Impact of new drugs and biologics on colorectal cancer treatment and costs', American Journal of Managed Care, vol. 17, no. 5.
    Karaca-Mandic, Pinar ; McCullough, Jeffrey S. ; Siddiqui, Mustaqeem A. ; Van Houten, Holly ; Shah, Nilay D. / Impact of new drugs and biologics on colorectal cancer treatment and costs. In: American Journal of Managed Care. 2011 ; Vol. 17, No. 5.
    @article{5cac5762faa64c6bbbea132049261729,
    title = "Impact of new drugs and biologics on colorectal cancer treatment and costs",
    abstract = "Objective: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens. Study Design: Using claims data, we identified 2 cohorts of privately insured patients diagnosed with CRC: first, those diagnosed before new treatment introduction (January 1, 2002, to December 31, 2002), and second, those diagnosed after new treatment introduction (June 1, 2004, to May 31, 2005). CRC diagnosis was identified using International Classification of Diseases-9 codes 153.xx, 154.xx, and 159.0. First- and second-line chemotherapy regimens were identified. Treatments and expenditures were then observed for up to 2 years after initial diagnosis. Methods: We estimated multivariate models to measure changes in cost with changes in treatment regimen. Approval dates of new regimens were used as natural experiments. Results: New regimens, such as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), have rapidly replaced the most prevalent preperiod product (ie, fluorouracil/leucovorin). Changes in treatment have caused large increases in total expenditure, primarily through increases in chemotherapy prices. FOLFOX alone has increased total average cost by 14{\%}. New treatments have not substituted for other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes in follow-up duration. Conclusion: New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.",
    author = "Pinar Karaca-Mandic and McCullough, {Jeffrey S.} and Siddiqui, {Mustaqeem A.} and {Van Houten}, Holly and Shah, {Nilay D.}",
    year = "2011",
    month = "5",
    day = "1",
    language = "English (US)",
    volume = "17",
    journal = "American Journal of Managed Care",
    issn = "1088-0224",
    publisher = "Ascend Media",
    number = "5",

    }

    TY - JOUR

    T1 - Impact of new drugs and biologics on colorectal cancer treatment and costs

    AU - Karaca-Mandic, Pinar

    AU - McCullough, Jeffrey S.

    AU - Siddiqui, Mustaqeem A.

    AU - Van Houten, Holly

    AU - Shah, Nilay D.

    PY - 2011/5/1

    Y1 - 2011/5/1

    N2 - Objective: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens. Study Design: Using claims data, we identified 2 cohorts of privately insured patients diagnosed with CRC: first, those diagnosed before new treatment introduction (January 1, 2002, to December 31, 2002), and second, those diagnosed after new treatment introduction (June 1, 2004, to May 31, 2005). CRC diagnosis was identified using International Classification of Diseases-9 codes 153.xx, 154.xx, and 159.0. First- and second-line chemotherapy regimens were identified. Treatments and expenditures were then observed for up to 2 years after initial diagnosis. Methods: We estimated multivariate models to measure changes in cost with changes in treatment regimen. Approval dates of new regimens were used as natural experiments. Results: New regimens, such as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), have rapidly replaced the most prevalent preperiod product (ie, fluorouracil/leucovorin). Changes in treatment have caused large increases in total expenditure, primarily through increases in chemotherapy prices. FOLFOX alone has increased total average cost by 14%. New treatments have not substituted for other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes in follow-up duration. Conclusion: New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.

    AB - Objective: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens. Study Design: Using claims data, we identified 2 cohorts of privately insured patients diagnosed with CRC: first, those diagnosed before new treatment introduction (January 1, 2002, to December 31, 2002), and second, those diagnosed after new treatment introduction (June 1, 2004, to May 31, 2005). CRC diagnosis was identified using International Classification of Diseases-9 codes 153.xx, 154.xx, and 159.0. First- and second-line chemotherapy regimens were identified. Treatments and expenditures were then observed for up to 2 years after initial diagnosis. Methods: We estimated multivariate models to measure changes in cost with changes in treatment regimen. Approval dates of new regimens were used as natural experiments. Results: New regimens, such as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), have rapidly replaced the most prevalent preperiod product (ie, fluorouracil/leucovorin). Changes in treatment have caused large increases in total expenditure, primarily through increases in chemotherapy prices. FOLFOX alone has increased total average cost by 14%. New treatments have not substituted for other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes in follow-up duration. Conclusion: New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.

    UR - http://www.scopus.com/inward/record.url?scp=79960224593&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79960224593&partnerID=8YFLogxK

    M3 - Article

    C2 - 21711066

    AN - SCOPUS:79960224593

    VL - 17

    JO - American Journal of Managed Care

    JF - American Journal of Managed Care

    SN - 1088-0224

    IS - 5

    ER -